儿童癫痫性痉挛中氨己烯酸剂量的群体药代动力学优化
本研究回顾性纳入79例儿童癫痫患者,建立氨己烯酸群体药代动力学模型,并在61例癫痫性痉挛患儿中分析暴露与疗效关系。模型显示体重和肌酐清除率是清除率的主要协变量,22例应答者中95%的AUC0-24在264–549 mg.h.L-1之间,提示可据此开展目标浓度干预以避免应答者过度暴露。
要点
- 体重和肌酐清除率是氨己烯酸清除率个体间变异的主要解释因素。
- 癫痫性痉挛应答者95%的AUC0-24范围为264–549 mg.h.L-1。
- 可基于该群体药代动力学模型开展目标浓度干预,避免应答者过度暴露。
核心结论
- 体重和肌酐清除率是解释氨己烯酸个体间变异的主要因素。
- 本研究定义了儿童癫痫性痉挛患者可接受的氨己烯酸暴露范围。
- 利用该药代动力学模型的目标浓度干预可避免应答者过度暴露。
研究设计与样本
- 回顾性研究纳入2019年1月至2022年1月在Necker-Enfants Malades医院随访并检测氨己烯酸浓度的癫痫儿童。
- 共纳入79例患者,分析159份样本,中位年龄4.2岁(范围0.3–18)。
- 使用Monolix2021以非线性混合效应模型方法建立群体药代动力学模型。
- 61例癫痫性痉挛患儿按痉挛是否缓解分为应答组和非应答组以识别有效暴露范围。
主要发现
- 含异速生长和肌酐清除率对清除率影响的二室模型对数据拟合最佳。
- 61例癫痫性痉挛患儿中22例应答(36%)。
- 22例应答者中95%的AUC0-24在264–549 mg.h.L-1之间。
关键数值与推荐
- 应答者95%的AUC0-24范围为264–549 mg.h.L-1。
临床怎么用
- 可依据体重和肌酐清除率调整儿童氨己烯酸剂量。
- 可利用该群体药代动力学模型开展目标浓度干预,避免应答者过度暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Vigabatrin is an antiepileptic drug used to treat some forms of severe epilepsy in children. The main adverse effect is ocular toxicity, which is related to the cumulative dose. The aim of the study is to identify an acceptable exposure range, both through the development of a population pharmacokinetic model of vigabatrin in children enabling us to calculate patient exposure and through the study of therapeutic response. METHODS: We performed a retrospective study including children with epilepsy followed at Necker-Enfants Malades hospital who had a vigabatrin assay between January 2019 and January 2022. The population pharmacokinetic study was performed on Monolix2021 using a nonlinear mixed-effects modelling approach. Children treated for epileptic spasms were classified into responder and nonresponder groups according to whether the spasms resolved, in order to identify an effective plasma exposure range. RESULTS: We included 79 patients and analysed 159 samples. The median age was 4.2 years (range 0.3-18). A 2-compartment model with allometry and creatinine clearance on clearance best fit our data. Exposure analysis was performed on 61 patients with epileptic spasms. Of the 22 patients who responded (36%), 95% had an AUC0-24 between 264 and 549 mg.h.L-1. CONCLUSIONS: The population pharmacokinetic model allowed us to identify bodyweight and creatinine clearance as the 2 main factors explaining the observed interindividual variability of vigabatrin. An acceptable exposure range was defined in this study. A target concentration intervention approach using this pharmacokinetic model could be used to avoid overexposure in responder patients.
引用
- Molimard A, Foissac F, Bouazza N, et al. Optimization of vigabatrin dosage in children with epileptic spasms: A population pharmacokinetic approach. Br J Clin Pharmacol. 2024. PMID: 38664899. doi:10.1111/bcp.16072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。